Phase II Study of Consolidation Chemotherapy after Adjuvant or Primary Concurrent Chemoradiation Using Paclitaxel and Carboplatin to Treat High-Risk Early-Stage or Locally Advanced Cervical Cancer / Journal of the Korean Cancer Association, 대한암학회지
Cancer Research and Treatment
; : 97-103, 2012.
Article
em En
| WPRIM
| ID: wpr-92991
Biblioteca responsável:
WPRO
ABSTRACT
PURPOSE:
This study investigated the efficacy and toxicity associated with consolidation chemotherapy using paclitaxel and carboplatin after concurrent chemoradiation (CCR) in cervical cancer patients. MATERIALS ANDMETHODS:
From a total of 37 patients, 19 with International Federation of Gynecology and Obstetrics (FIGO) stage IB1-IIA cervical cancer (group 1) underwent surgery followed by consolidation chemotherapy after CCR, and 18 with stage IIB-IVA disease (group 2) received consolidation chemotherapy after primary CCR. Three cycles of chemotherapy using paclitaxel (135 mg/m2) and carboplatin (AUC 5.0) were administered every 3 weeks for CCR therapy, and three cycles of consolidation chemotherapy using paclitaxel (175 mg/m2) and carboplatin (AUC 5.0) were used every 3 weeks after CCR.RESULTS:
The complete and partial response rates were 77.8% and 22.2% in group 2. Moreover, the 3-year progression-free and overall survival rates were 62.7% and 90.9% in group 1, and 51.9% and 60% in group 2, respectively. The most common grade 3 or 4 hematologic toxicities observed were leukopenia (group 1, 10.5%; group 2, 13.0%) and neutropenia (group 1, 7.0%; group 2, 14.8%), and grade 3 or 4 diarrhea (group 1, 1.8%) and febrile illness (group 2, 1.9%) were the most frequently observed non-hematologic toxicities. When we compared these results with previous reports, consolidation chemotherapy after CCR using paclitaxel and carboplatin revealed a relatively lower complete response rate (77.8% vs. 87-100%, respectively) and shorter progression-free survival (51.9-62.7% vs. 81-86%, respectively) and overall survival (60-90.9% vs. 81-95%, respectively) in spite of similar toxicity findings.CONCLUSION:
Due to low efficacy results, consolidation chemotherapy using paclitaxel and carboplatin after CCR is not a feasible treatment regimen for high-risk early-stage or locally advanced cervical cancer.Palavras-chave
Texto completo:
1
Índice:
WPRIM
Assunto principal:
Neoplasias do Colo do Útero
/
Taxa de Sobrevida
/
Carboplatina
/
Paclitaxel
/
Intervalo Livre de Doença
/
Diarreia
/
Quimiorradioterapia
/
Quimioterapia de Consolidação
/
Ginecologia
/
Leucopenia
Tipo de estudo:
Etiology_studies
Limite:
Humans
Idioma:
En
Revista:
Cancer Research and Treatment
Ano de publicação:
2012
Tipo de documento:
Article